儿童支气管哮喘治疗药物研究进展  

Progress in drug treatment for children with bronchial asthma

作　　者：王晓阳(综述) 刘传合(审校)[1] Wang Xiaoyang;Liu Chuanhe(Department of Allergy,Children′s Hospital of Capital Institute of Pediatrics,Beijing 100020,China)

机构地区：[1]首都儿科研究所附属儿童医院变态反应科,北京100020

出　　处：《国际儿科学杂志》2020年第3期151-154,共4页International Journal of Pediatrics

基　　金：北京市医院管理局重点医学专业发展计划(ZYLX201829);国家重点研发计划"精准医学研究"专项(2016YFC0901103)。

摘　　要：药物治疗是儿童支气管哮喘长期管理的主要手段。但支气管哮喘是一种异质性疾病,少数患者虽然规律用药,其哮喘仍控制不佳,需探索新的治疗方法和技术。随着对支气管哮喘发病机制研究的不断深入,许多新的药物被研发,尤其是以单克隆抗体为主导的靶向药物,已成为支气管哮喘治疗的研究热点。Pharmacotherapy is the main part of management of bronchial asthma in children.However,due to the heterogeneity of bronchial asthma,some patients are poorly controlled despite regular medication.Thus new drug and technologies need to be explored.With deep understanding of the pathogenesis of bronchial asthma,a lot of new drugs were available to asthmatic patients,especially the targeted drugs dominated by monoclonal antibodies,which have become the hot spot of bronchial asthma treatment.

关 键 词：儿童 支气管哮喘 药物 

分 类 号：R56[医药卫生—呼吸系统]